137 related articles for article (PubMed ID: 34955348)
1. Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients.
Tabrizian P; Saberi B; Holzner ML; Rocha C; Kyung Jung Y; Myers B; Florman SS; Schwartz ME
HPB (Oxford); 2022 Jul; 24(7):1082-1090. PubMed ID: 34955348
[TBL] [Abstract][Full Text] [Related]
2. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
Flemming JA; Kim WR; Brosgart CL; Terrault NA
Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
[TBL] [Abstract][Full Text] [Related]
3. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.
Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738
[TBL] [Abstract][Full Text] [Related]
4. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
5. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
6. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
Lockart I; Hajarizadeh B; Buckley N; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
J Gastroenterol Hepatol; 2021 Dec; 36(12):3515-3523. PubMed ID: 34520088
[TBL] [Abstract][Full Text] [Related]
7. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
Kwong AJ; Kim WR; Flemming JA
Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
[TBL] [Abstract][Full Text] [Related]
8. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades.
Puigvehí M; Hashim D; Haber PK; Dinani A; Schiano TD; Asgharpour A; Kushner T; Kakked G; Tabrizian P; Schwartz M; Gurakar A; Dieterich D; Boffetta P; Friedman SL; Llovet JM; Saberi B
Am J Transplant; 2020 Jan; 20(1):220-230. PubMed ID: 31437349
[TBL] [Abstract][Full Text] [Related]
9. Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era.
Okumura K; Sogawa H; Samson D; Butler J; Veillette G; John D; Diflo T; Bodin R; Wolf DC; Latifi R; Nishida S
Transplant Proc; 2022 Sep; 54(7):1834-1838. PubMed ID: 35933231
[TBL] [Abstract][Full Text] [Related]
10. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
[TBL] [Abstract][Full Text] [Related]
11. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
[TBL] [Abstract][Full Text] [Related]
12. HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.
Emamaullee JA; Bral M; Meeberg G; Montano-Loza AJ; Bain VG; Burak KW; Bigam D; Shapiro AMJ; Kneteman N
Can J Gastroenterol Hepatol; 2019; 2019():2509059. PubMed ID: 30775356
[TBL] [Abstract][Full Text] [Related]
13. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
14. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.
Daniel KE; Said A
Curr Gastroenterol Rep; 2018 Apr; 20(5):20. PubMed ID: 29623506
[TBL] [Abstract][Full Text] [Related]
15. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.
Young K; Liu B; Bhuket T; Wong RJ
J Clin Exp Hepatol; 2020; 10(6):581-589. PubMed ID: 33311895
[TBL] [Abstract][Full Text] [Related]
16. Liver Transplantation for Hepatitis B in Early Adulthood: Analysis of the United Network for Organ Sharing Database.
Rifai G; Anani A; Hanouneh IA; Mohamad B; Matloob A; Lopez R; Zein NN; Alkhouri N
Transplant Proc; 2016 Dec; 48(10):3362-3367. PubMed ID: 27931582
[TBL] [Abstract][Full Text] [Related]
17. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.
Franssen B; Alshebeeb K; Tabrizian P; Marti J; Pierobon ES; Lubezky N; Roayaie S; Florman S; Schwartz ME
Ann Surg; 2014 Oct; 260(4):650-6; discussion 656-8. PubMed ID: 25203882
[TBL] [Abstract][Full Text] [Related]
18. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
19. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.
Kanda T; Lau GKK; Wei L; Moriyama M; Yu ML; Chuang WL; Ibrahim A; Lesmana CRA; Sollano J; Kumar M; Jindal A; Sharma BC; Hamid SS; Kadir Dokmeci A; Mamun-Al-Mahtab ; McCaughan GW; Wasim J; Crawford DHG; Kao JH; Ooka Y; Yokosuka O; Sarin SK; Omata M
Hepatol Int; 2019 Nov; 13(6):649-661. PubMed ID: 31541423
[TBL] [Abstract][Full Text] [Related]
20. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
